ArticleThe world journal of men's health2016
The Efficacy of Medical Treatment of Peyronie's Disease: Potassium Para-Aminobenzoate Monotherapy vs. Combination Therapy with Tamoxifen, L-Carnitine, and Phosphodiesterase Type 5 Inhibitor.
Article in The world journal of men's health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-surgical therapies for Peyronie's disease.The Cochrane database of systematic reviews · 2023Pooled it
- [Gender differences in acylcarnitine metabolism among patients with depression disorder].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- Acute Phase Peyronie's Disease: Where Do We Stand?Cureus · 2024Review
- Conservative treatment of Peyronie's disease: a guide.World journal of urology · 2024Review
- Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Current urology reports · 2021Review
- Peyronie's disease - outcomes of collagenaseArab journal of urology · 2021Review
- Minimally invasive therapies for Peyronie's disease: the current state of the art.Translational andrology and urology · 2020Review
- Recent advances in managing Peyronie's disease.F1000Research · 2020Review
- Extracorporeal Shock Wave Therapy in Peyronie's Disease: Clinical Efficacy and Safety from a Single-Arm Observational Study.The world journal of men's health · 2019Article
- Collagenase clostridium hystolyticum in the management of Peyronie's disease.Translational andrology and urology · 2017Article
- Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.Research and reports in urology · 2017Article
- Nonsurgical Interventions for Peyronie's Disease: Update as of 2016.The world journal of men's health · 2016Review
- ---F1000Research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was designed to evaluate the efficacy of medical treatment of Peyronie's disease. MATERIALS AND
methodsA total of 109 patients with Peyronie's disease who had been treated from January 2011 to December 2014 were retrospectively reviewed in this study. Forty-four patients (Group 1) were treated with 12 mg of potassium para-aminobenzoate daily. Sixty-five patients (Group 2) were treated with combination therapy: tamoxifen (20 mg) and acetyl-L-carnitine (300 mg) twice daily in addition to a phosphodiesterase type 5 inhibitor. Ability to perform sexual intercourse, pain during erection, size of plaque, and penile curvature angle were assessed.
resultsIn Group 1, 30 of 44 patients (68.2%) discontinued treatment within 12 weeks, while 5 patients (7.7%) in Group 2 discontinued treatment. Pain during erection and plaque size were improved in both groups but showed no statistical difference due to the high dropout rate in Group 1. In both groups, penile curvature was improved, but demonstrated no statistical difference between the treatment groups. However, combination therapy demonstrated a better response rate in patients whose penile curvature angle was less than 30° (44.4% vs. 79.1%, p=0.048). The rate of successful sexual intercourse was significantly higher in Group 2 (42.8% vs. 78.3%, p=0.034). The number of patients who underwent surgical correction despite medical treatment was significantly higher in Group 1 (35.7% vs. 13.3%, p=0.048).
conclusionsEarly medical combination therapy in Peyronie's disease may present better results in patients whose curvature angle is less than 30°.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.